Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Starr

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
Molecular Cancer Therapeutics|February 20, 2015
Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimusYingmiao Liu, Mark D Starr, John C Brady, et al.
Clinical Genitourinary Cancer|April 2, 2014
A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinomaRhonda L Bitting, Patrick Healy, Patricia A Creel, et al.
Gynecologic Oncology|April 2, 2019
Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancerAngeles Alvarez Secord, Michael McCollum, Brittany A Davidson, et al.
Prostate Cancer and Prostatic Diseases|February 12, 2024
Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumabAndrew B Nixon, Yingmiao Liu, Qian Yang, et al.
Icarus|August 12, 2017
Moonshine: Diurnally varying hydration through natural distillation on the Moon, detected by the Lunar Exploration Neutron Detector (LEND)T A Livengood, G Chin, R Z Sagdeev, et al.
JCI Insight|January 8, 2025
Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapyJoyce Hwang, Eda Holl, Yuan Wu, et al.
Pharmacogenetics|November 24, 1998
Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6S F Worrall, M Corrigan, A High, et al.
Science (New York, N.Y.)|October 1, 2011
MESSENGER observations of transient bursts of energetic electrons in Mercury's magnetosphereGeorge C Ho, Stamatios M Krimigis, Robert E Gold, et al.
Cancer Medicine|August 10, 2013
A phase I study of ABT-510 plus bevacizumab in advanced solid tumorsHope E Uronis, Stephanie M Cushman, Johanna C Bendell, et al.
Radiology|August 9, 2017
Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular CarcinomaJames Ronald, Andrew B Nixon, Daniele Marin, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Molecular Cancer Therapeutics|February 20, 2015
Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimusYingmiao Liu, Mark D Starr, John C Brady, et al.
Clinical Genitourinary Cancer|April 2, 2014
A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinomaRhonda L Bitting, Patrick Healy, Patricia A Creel, et al.
Gynecologic Oncology|April 2, 2019
Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancerAngeles Alvarez Secord, Michael McCollum, Brittany A Davidson, et al.
Prostate Cancer and Prostatic Diseases|February 12, 2024
Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumabAndrew B Nixon, Yingmiao Liu, Qian Yang, et al.
Icarus|August 12, 2017
Moonshine: Diurnally varying hydration through natural distillation on the Moon, detected by the Lunar Exploration Neutron Detector (LEND)T A Livengood, G Chin, R Z Sagdeev, et al.
JCI Insight|January 8, 2025
Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapyJoyce Hwang, Eda Holl, Yuan Wu, et al.
Pharmacogenetics|November 24, 1998
Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6S F Worrall, M Corrigan, A High, et al.
Science (New York, N.Y.)|October 1, 2011
MESSENGER observations of transient bursts of energetic electrons in Mercury's magnetosphereGeorge C Ho, Stamatios M Krimigis, Robert E Gold, et al.
Cancer Medicine|August 10, 2013
A phase I study of ABT-510 plus bevacizumab in advanced solid tumorsHope E Uronis, Stephanie M Cushman, Johanna C Bendell, et al.
Radiology|August 9, 2017
Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular CarcinomaJames Ronald, Andrew B Nixon, Daniele Marin, et al.
Pageof 9